11:42 AM
 | 
Jan 26, 2018
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Follow-on roundup: Ultragenyx, Adamas, Rocket

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) raised $250 million on Jan. 23 through the sale of 4.4 million shares at $57 in a bumped-up follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Goldman Sachs and Cowen. The price is a 7% premium to Ultragenyx's close of $53.39 on Jan. 22, when it proposed after market hours to raise $175 million.

The company gained a combined $8.98 (18%) on Jan. 22 and Jan. 23 as the market digested news of multi-billion life science deals, including the takeouts of gene...

Read the full 421 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >